GT200800269A - Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina - Google Patents

Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina

Info

Publication number
GT200800269A
GT200800269A GT200800269A GT200800269A GT200800269A GT 200800269 A GT200800269 A GT 200800269A GT 200800269 A GT200800269 A GT 200800269A GT 200800269 A GT200800269 A GT 200800269A GT 200800269 A GT200800269 A GT 200800269A
Authority
GT
Guatemala
Prior art keywords
determined
swine fever
structural glycoprotein
new virulence
hil
Prior art date
Application number
GT200800269A
Other languages
English (en)
Inventor
Borca Manuel
Risatti Guillermo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200800269A publication Critical patent/GT200800269A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24361—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA INVENCIÓN PROPORCIONA ANTICUERPOS HUMANOS, PREFERIBLEMENTE ANTICUERPOS HUMANOS RECOMBINANTES, QUE SE UNEN ESPECÍFICAMENTE AL RECEPTOR DE INTERLEUCINA - 6 - HUMANA, HIL-6R. ESTOS ANTICUERPOS SE CARACTERIZAN POR UNIRSE A HIL-6R CON ELEVADA AFINIDAD Y LENTA CINÉTICA DE DISOCIACIÓN, Y POR SU CAPACIDAD DE NEUTRALIZAR LA ACTIVIDAD DE IL-6. ADEMÁS SE PRESENTA UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE UN ANTICUERPO O FRAGMENTO DE UNIÓN A ANTÍGENO DE UN ANTICUERPO ANTES MENCIONADO, Y UN MÉTODO PARA ATENUAR O INHIBIR UNA ENFERMEDAD O TRASTORNO EN QUE INTERVIENE IL-6 EN UN PACIENTE HUMANO. T2008
GT200800269A 2006-05-30 2008-12-01 Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina GT200800269A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/443,132 US8846055B2 (en) 2006-05-30 2006-05-30 Virulence determinant within the E2 structural glycoprotein of classical swine fever virus

Publications (1)

Publication Number Publication Date
GT200800269A true GT200800269A (es) 2009-05-04

Family

ID=38790491

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200800269A GT200800269A (es) 2006-05-30 2008-12-01 Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina

Country Status (14)

Country Link
US (1) US8846055B2 (es)
EP (1) EP2023953B1 (es)
JP (1) JP5377296B2 (es)
KR (1) KR101432840B1 (es)
CN (1) CN101478985B (es)
BR (1) BRPI0712558A2 (es)
CA (1) CA2656560A1 (es)
CR (1) CR10508A (es)
GT (1) GT200800269A (es)
MX (1) MX2008015215A (es)
RU (1) RU2451746C2 (es)
UA (1) UA98620C2 (es)
WO (1) WO2007143442A2 (es)
ZA (1) ZA200810285B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114852B2 (en) * 2008-01-15 2012-02-14 The United States Of America As Represented By The Secretary Of Agriculture N-linked glycosylation alteration in E1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine
US20100104597A1 (en) * 2008-10-24 2010-04-29 Manuel Borca N-linked glycosylation alteration in E0 and E2 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine
EP2202298A1 (en) * 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
MX337048B (es) 2010-05-18 2016-02-11 Riemser Arzneimittel Ag Vacuna marcadora para la fiebre porcina clasica.
CN102175849B (zh) * 2010-12-22 2013-07-03 江苏出入境检验检疫局动植物与食品检测中心 一种快速检测猪瘟抗体的试剂盒及其制备方法
CN102268079B (zh) * 2011-05-03 2013-04-03 新乡学院 猪瘟病毒csfv e2蛋白配体表位多肽及其应用
CN103499693A (zh) * 2013-10-11 2014-01-08 重庆出入境检验检疫局检验检疫技术中心 猪瘟病毒抗体竞争AlphaLISA检测试剂盒及检测方法
RU2689143C1 (ru) 2013-12-19 2019-05-24 Интервет Интернэшнл Б.В. Усовершенствованный диагностический тест для csfv антител
DK3146042T3 (da) * 2014-05-23 2019-09-30 Boehringer Ingelheim Vetmedica Gmbh Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop
CN104483490B (zh) * 2014-12-09 2016-06-08 武汉科前生物股份有限公司 一种猪瘟病毒阻断elisa抗体检测试剂盒及应用
US9814771B2 (en) * 2015-09-11 2017-11-14 The United States Of America, As Represented By The Secretary Of Agriculture Live attenuated classical swine fever vaccine based in genetic manipulation of a putative fusion peptide area in the virus structural glycoprotein E2
CN109563518A (zh) * 2016-05-12 2019-04-02 巴伊沃爱普有限公司 来自植物的用于经典猪瘟的疫苗组合物及其制造方法
US9808520B1 (en) * 2016-07-01 2017-11-07 The United States Of America As Represented By The Secretary Of Agriculture Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate
CN106749519B (zh) * 2016-11-15 2020-04-07 河南省农业科学院 基于计算机模拟的csfv e2蛋白靶向结合的肽配基序列设计及应用
CN109324193A (zh) * 2018-12-07 2019-02-12 中国农业科学院兰州兽医研究所 一种猪瘟病毒抗体的可视化快速检测试剂盒及其应用
CN112961224B (zh) * 2021-03-26 2022-09-27 中国农业大学 牛病毒性腹泻病毒1型病毒样颗粒的制备及应用
EP4105225A1 (en) * 2021-06-18 2022-12-21 Institut de Recerca i Tecnologia Agroalimentàries Peptide-based assay to differentiate animals infected with csfv from vaccinated animals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0982402A1 (en) * 1998-08-14 2000-03-01 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Pestivirus vaccination

Also Published As

Publication number Publication date
JP2009538628A (ja) 2009-11-12
CN101478985B (zh) 2013-10-30
CR10508A (es) 2009-02-23
UA98620C2 (uk) 2012-06-11
BRPI0712558A2 (pt) 2012-11-20
EP2023953A4 (en) 2010-01-20
MX2008015215A (es) 2009-02-06
US8846055B2 (en) 2014-09-30
RU2451746C2 (ru) 2012-05-27
WO2007143442A2 (en) 2007-12-13
KR101432840B1 (ko) 2014-09-22
KR20090025291A (ko) 2009-03-10
RU2008150400A (ru) 2010-07-10
JP5377296B2 (ja) 2013-12-25
EP2023953A2 (en) 2009-02-18
WO2007143442A3 (en) 2008-03-13
EP2023953B1 (en) 2014-11-19
ZA200810285B (en) 2010-07-28
CN101478985A (zh) 2009-07-08
US20070280955A1 (en) 2007-12-06
CA2656560A1 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
GT200800269A (es) Una novedosa virulencia determinada dentro de la glicoproteina estructural e2 del virus clasico de la fiebre porcina
AR082149A1 (es) Anticuerpos contra el virus sincicial respiratorio (rsv) humano y metodos para su uso
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
UA109633C2 (uk) Антитіло людини проти тканинного фактора
DOP2019000006A (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
CO6331300A2 (es) Composicion que comprende un anticuerpo monoclonal o el anticuerpo scfv enlazado a un epitopo en la region de tallo de la proteina de hemaglutinina (ha)
CL2016002624A1 (es) Anticuerpos humanos que se unen al gen 3 de activación linfocitaria (lag-3) y los usos de estos (divisional sol. n°0308-2011)
AR069290A1 (es) Anticuerpos monoclonales que se unen al hgm -csf (factor estimulante de la colonia de granulocitos-macrofagos) y las composiciones medicas que los comprenden
CL2008002923A1 (es) Anticuerpo monoclonal humano aislado porque se adhiere a mesotelina humana; composicion que comprende dicho anticuerpo; conjugado entre anticuerpo y agente terapeutico; molecula de acido nucleico que codifica el anticuerpo; uso para preparar un medicamento para tratar cancer.
NO20083793L (no) Antistoffer mot amyloid-beta peptid
BR112015014751A8 (pt) anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
CR10298A (es) Metodos y composiciones para antagonismo de rage
CO6400149A2 (es) Proteínas de enlace a miostatina
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
AR073720A1 (es) Anticuerpos humanizados de endoglina
BRPI0412890B8 (pt) método de selecionar um anticorpo anti kir2dl1 ou fragmento de anticorpo de ligação de antígeno
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
ECSP12012272A (es) Proteínas que se unen al tnf-?
BRPI0819916A2 (pt) Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
AR078423A1 (es) Vacunas dirigidas a las celulas de langerhans
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
CL2012001650A1 (es) Fragmento fab de anticuerpo que se une específicamente a la glicoproteína vi (gpvi) humana e induce un fenotipo de reducción de gpvi; composición farmacéutica que comprende dichos fragmentos fab de anticuerpo anti-gpvi; polinucleótido que los codifica; método para su preparación; su uso para evitar el reconocimiento de un fragmento fab de anticuerpo por anticuerpos preexistentes; y su uso para evitar la activación plaquetaria mediante el enmascaramiento del c-terminal de dicho fragmento fab.